COMMUNIQUÉS West-GlobeNewswire
-
Oncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026
18/06/2026 -
23andMe Research Institute Appoints Hillary Aiken as Head of Philanthropy & Development
18/06/2026 -
R1 Accelerates Real-Time Adjudication with New Phare OS Intelligence Engine
18/06/2026 -
Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update
18/06/2026 -
Bionano Announces 67% Year-Over-Year Growth in Studies Featuring Optical Genome Mapping at ESHG 2026, Reflecting Expanding Global Adoption
18/06/2026 -
Halberd Corporation Ships Latest NeuroSense AI Version, Advancing Voice-Based Behavioral Monitoring
18/06/2026 -
Breckenridge Distillery Releases Limited Single Barrel Bourbon Collection
18/06/2026 -
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
18/06/2026 -
Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
18/06/2026 -
Zelluna ASA: Disclosure of large shareholding
18/06/2026 -
New analyses from FIBRONEER™ trials suggest survival benefit with nerandomilast in IPF and PPF
18/06/2026 -
BIO-Europe unveils renewed vision as the must-attend global biopharma strategy forum
18/06/2026 -
Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
18/06/2026 -
FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma
18/06/2026 -
Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470
18/06/2026 -
Nicox annonce des retours réglementaires préalables positifs en Chine soutenant le dépôt du NDA pour NCX 470
18/06/2026 -
F2G and Shionogi Announce Positive Topline Results From Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients With Invasive Aspergillosis
18/06/2026 -
Legend Biotech Corporation Announces Pricing of Public Offering
18/06/2026 -
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
18/06/2026
Pages